Les Meilleures Cliniques et Coûts pour Votre Thérapie au lutétium-177 en Israël en 2026

Lutetium-177 therapy in Israel is a targeted nuclear medicine treatment for metastatic prostate cancer and neuroendocrine tumors. Using PSMA or DOTATATE ligands, it delivers precise beta radiation to malignant cells. Leading JCI-accredited centers like Sourasky and Hadassah offer this molecular therapy to international patients.

• Treatment protocol: Administration occurs in 3–4 doses at intervals of 8 weeks.
• Infusion duration: Each session requires only a 10-minute intravenous infusion time.
• Cost profile: Therapy costs $16,500 to $22,800, saving patients up to 56%.
• Expert centers: Sourasky treats 40,000 cancer patients annually using advanced molecular techniques.

Bookimed Expert Insight: Israeli oncology centers like Sourasky provide a unique advantage by integrating Foundation One CDx genetic testing with Lutetium-177 protocols. This ensures your specific tumor biology matches the radioligand before you commit to the full $16,500 treatment cycle. It helps avoid ineffective therapy sessions.

Patient Consensus: Patients emphasize the necessity of confirming receptor expression via PET scan first. Many suggest using ice chips during the infusion to successfully manage dry mouth symptoms.

Lutetium-177 therapy is generally well-tolerated, though it carries risks like bone marrow suppression, kidney toxicity, and xerostomia. Patients often experience temporary fatigue and nausea during the first week. In Israel, specialists at JCI-accredited centers use precise dosing to manage these radiation-related side effects effectively.

• Blood counts: Temporary drops in red and white cells require regular monitoring.
• Salivary glands: Dry mouth affects many patients and can sometimes become partially irreversible.
• Kidney health: Protective amino acid infusions help prevent radiation damage during treatment.
• Fatigue levels: Most patients report significant exhaustion lasting approximately 7 days post-infusion.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center maintain a high 90% success rate by integrating medical physicists into the care team. Experts like Dr. Inna Ospovat use advanced protocols to shield healthy organs. This multidisciplinary approach ensures radiation hits the tumor while minimizing long-term damage to the kidneys and salivary glands.

Patient Consensus: Many patients find managing dry mouth with sour candies helpful. Most emphasize the need for total rest during the first week due to sudden, intense fatigue.

Lutetium-177 therapy effectively extends lives by delivering targeted radiation to cancer cells. Patients often see median survival rates increase to 15.3 months, compared to 11.3 months with standard care. This molecular therapy significantly reduces PSA levels in 30% to 70% of advanced cases.

• Survival benefit: Reduces the risk of death by 38% for metastatic prostate cancer patients.
• Progression delay: Delays cancer growth for 8.7 months versus 3.4 months with conventional treatments.
• Tumor response: Approximately 75–80% of patients experience measurable tumor shrinkage or declining PSA levels.
• Treatment cycle: Standard protocols involve intravenous administration every 7 to 8 weeks for efficacy.

Bookimed Expert Insight: Israeli centers like Sourasky Medical Center provide targeted Lutetium-177 therapy for $16,500 to $22,800. This is roughly 56% less than the $45,000 US average. Expert Nuclear Therapy Specialist Dr. Inna Ospovat emphasizes that completing 5 or more cycles significantly improves survival outcomes compared to shorter courses.

Patient Consensus: While not a cure, patients frequently report better quality of life and reduced bone pain. Many note that managing dry mouth early is vital as this side effect can become permanent without proactive monitoring.

Lu-177 therapy involves intravenous infusion of radioactive isotopes to target prostate or neuroendocrine tumors. Preparation requires PET/CT imaging to confirm receptor expression and blood tests for kidney function. The procedure lasts 4 hours as a daycare visit, with patients following radiation safety protocols for 3 days post-treatment.

• Pre-treatment imaging: PET/CT scans confirm cancer cells express receptors for targeted isotope delivery.
• Medication protocol: Patients must stop long-acting octreotide 4 weeks before treating neuroendocrine tumors.
• Infusion process: The radioactive dose takes 10–30 minutes within a 4-hour hydration session.
• Renal protection: Amino acid solutions infuse via IV to protect kidneys from radiation exposure.

Bookimed Expert Insight: Israeli centers like Sourasky Medical Center provide Lu-177 through a multi-disciplinary team led by specialists like Inna Ospovat. While the radioactive injection is brief, the full appointment is a 4-hour process due to mandatory pre-hydration and amino acid infusions. Proactive use of sugar-free gum helps manage xerostomia, a common cumulative side effect observed in patients undergoing multiple cycles.

Patient Consensus: Patients emphasize the importance of sitting while urinating and sleeping separately for 3 days to protect family. Most report manageable fatigue and advise bringing comfort items for the long daycare infusion sessions.

Lutetium-177 therapy is available at JCI-accredited facilities in Israel like Sourasky Medical Center and Hadassah Medical Center. Specialized nuclear medicine departments utilize Peptide Receptor Radionuclide Therapy (PRRT) and PSMA ligands to treat metastatic prostate cancer and neuroendocrine tumors through high-precision intravenous administration.

• Available locations: Tel Aviv Sourasky (Ichilov), Hadassah in Jerusalem, and Sheba Medical Center.
• Expert specialists: Dr. Inna Ospovat and Professor Amit Tirosh lead advanced nuclear oncology teams.
• Advanced diagnostics: Clinics utilize theranostics, combining PET/CT imaging with targeted molecular radiation therapy.
• Treatment cycle: Therapy typically requires 3 to 4 doses spaced 8 weeks apart.

Bookimed Expert Insight: Sourasky Medical Center treats 40,000 cancer patients annually using tools like the Novalis TrueBeam accelerator. While treatment costs $16,500 to $22,800 here, it remains highly competitive. You save approximately 56% compared to US prices of $45,000.

Patient Consensus: Patients emphasize that this targeted radioligand treatment is a vital option for metastatic cases. Many advise confirming eligibility with oncology centers regarding previous failures in hormone or chemotherapy.